Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASST. SECTY. FOR HEALTH BRANDT UNDER CONSIDERATION FOR U. TEXAS

Executive Summary

ASST. SECTY. FOR HEALTH BRANDT UNDER CONSIDERATION FOR U. TEXAS Medical School (San Antonio) Health Science Center presidency. Brandt is one of "six-to-eight" candidates interviewed for the position by a search cmte. appointed in February by the university's Board of Regents. The regents are scheduled to meet in October to review the search cmte.'s recommendations and select the new president. Under board procedures, the search cmte. would submit its three-to-five top choices to the board for final consideration. Current center president Frank Harrison plans to retire. Brandt, appointed in the early months of the Reagan Administration, has held the asst. secty. post longer than any of his recent predecessors. Surgeon General Koop, appointed in tandem with Brandt, joins the asst. secty. as part of Reagan's old guard at HHS. The selection of Brandt as the Health Science Center president would mean a return to familiar turf for the three and a half year Reagan Administration verteran. Prior to his HHS appointment, Brandt served as University of Texas Vice Chancellor for Health Affairs (1977-1981) and before that as University of Texas Medical Branch at Galveston graduate dean, associate dean for clinical affairs, dean of medicine, and professor of preventive medicine and family medicine (1970-1977).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel